For example, in the case of Angelman syndrome, if MS-MLPA identifies a maternal deletion in the Angelman syndrome critical region, the recurrence risks for the family is ~1%, while if a pathogenic sequence variant in UBE3A is found to be maternally inherited, the recurrence risks will be 50% [16]. This evidence concerns the gene UBE3A and Angelman syndrome.